• 1
    Sanda MG, Dunn RL, Michalski J et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358: 125061
  • 2
    Stock RG, Stone NN, Iannuzzi C. Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 1996; 35: 26772
  • 3
    Zagar TM, Stock RG, Cesaretti JA, Stone NN. Assessment of postbrachytherapy sexual function: a comparison of the IIEF-5 and the MSEFS. Brachytherapy 2007; 6: 2633
  • 4
    Stone NN, Stock RG. Prostate brachytherapy: treatment strategies. J Urol 1999; 162: 4216
  • 5
    Stock RG, Stone NN, Wesson MF, DeWyngaert JK. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 1995; 32: 21925
  • 6
    Stone NN, Ramin SA, Wesson MF, Stock R, Unger P, Klein G. Laparoscopic pelvic lymph node dissection combined with real-time interactive transrectal ultrasound guided transperineal radioactive seed implantation of the prostate. J Urol 1995; 153: 155560
  • 7
    Stock RG, Stone NN, Tabert A, Iannuzzi C, DeWyngaert JK. A dose–response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 1998; 41: 1018
  • 8
    Stock RG, Stone NN, Lo YC, Malhado N, Kao J, DeWyngaert JK. Postimplant dosimetry for (125)I prostate implants: definitions and factors affecting outcome. Int J Radiat Oncol Biol Phys 2000; 48: 899906
  • 9
    Potters L, Cao Y, Calugaru E, Torre T, Fearn P, Wang XH. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2001; 50: 60514
  • 10
    Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys 1995; 22: 20934
  • 11
    Beyer D, Nath R, Butler W et al. American brachytherapy society recommendations for clinical implementation of NIST-1999 standards for (103)palladium brachytherapy. The clinical research committee of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 2000; 47: 2735
  • 12
    Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2009; 75: 1622
  • 13
    Kaplan EL, Meier P. Nonparametric-estimation from incomplete observations. J Am Stat Assoc 1958; 53: 45781
  • 14
    Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 16370
  • 15
    Cox DR. Regression models and life-tables. J R Stat Soc Ser B 1972; 34: 187220
  • 16
    Merrick GS, Butler WM, Galbreath RW, Stipetich RL, Abel LJ, Lief JH. Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002; 52: 893902
  • 17
    Merrick GS, Butler WM, Wallner KE et al. Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005; 62: 43747
  • 18
    Stone NN, Stock RG. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology 2007; 69: 33842
  • 19
    Stock RG, Kao J, Stone NN. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 2001; 165: 4369
  • 20
    Potters L, Torre T, Fearn PA, Leibel SA, Kattan MW. Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2001; 50: 123542